Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
NCT07122895Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Scale for Assessment of Negative Symptoms Total Score at 12 weeks. Started Sep 2025; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07122895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122895.